Status:
UNKNOWN
Norwegian Coronavirus Disease 2019 Study
Lead Sponsor:
University Hospital, Akershus
Conditions:
Corona Virus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
In the current proposal, the investigators aim to investigate the virological and clinical effects of chloroquine treatment in patients with established COVID-19 in need of hospital admission. Patient...
Detailed Description
Chloroquine is one of two therapeutics (in addition to remdesivir) that has demonstrated in vitro inhibitory effects on SARS-CoV-2 and the drug is immediately available from national pharmacies. No de...
Eligibility Criteria
Inclusion
- Hospitalised
- Adults 18 year or older
- Moderately severe disease (NEWS score ≤ 6)
- SARS-CoV-2 positive nasopharyngeal swab
- Expected time of admission \> 48 hours
- Signed informed consent must be obtained and documented according to ICH GCP, and national/local regulations.
Exclusion
- Requiring ICU admission at screening
- History of psoriasis
- Known adverse reaction to hydroxychloroquine sulphate
- Pregnancy
- Prolonged QT interval (\>450 ms)
Key Trial Info
Start Date :
March 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 3 2025
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT04316377
Start Date
March 25 2020
End Date
March 3 2025
Last Update
June 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akershus University Hospital
Lørenskog, Norway, 1478